SCCS Preliminary Opinion on Genistein and Daidzein
The European Commission Scientific Committee on Consumer Safety (SCCS) has published its preliminary opinion on the use of Genistein and Daidzein in cosmetic products. The deadline for comments was set at 14 March 2022.
Marta Pinto

Marta Pinto

Regulatory Affairs Associate

GENISTEIN AND DAIDZEIN

Genistein (CAS number: 446-72-0) and Daidzein (CAS number: 486-66-8) are isoflavones, which are phenolic compounds classified as phytoestrogen. Phytoestrogens are plant-derived compounds structurally similar to 17β-estradiol (steroid hormone produced primarily by the ovaries during reproductive lifespan). Isoflavones can be naturally found in legumes (soybeans, chickpeas, fava beans), in fruits and nuts (e.g., peanuts).

In cosmetics and personal care products, Genistein and Daidzein are used as skin conditioning agents. Both ingredients are usually used in leave-on formulations. Genistein and Daidzein are not currently included in the annexes of the European Cosmetics Regulation (No. 1223/2009), which means that their use is not restricted in cosmetic products placed in the European Union (EU).

In early 2019, a priority list of 28 potential endocrine disruptors (not already covered by the bans of cosmetic regulation) was established by the Commission. From these 28 substances, 14 were considered as higher priority (Group A) and the other 14 were included in the low priority group (Group B). The public call for data for the considered higher priority substances was carried out in 2019. Genistein and Daidzein were included in the mentioned group for which the call of data took place. (see previous post)

During the call for data, stakeholders submitted scientific evidence to demonstrate the safety of Genistein and Daidzein in cosmetic products. The European Commission asked the Scientific Committee on Consumer Safety (SCCS) to carry out a safety assessment on these two substances considering the information provided.

NEW SCCS PRELIMINARY OPINION

This month, the SCCS has published its preliminary opinion on the use of Genistein and Daidzein in cosmetic products.

Considering the potential endocrine disrupting properties of phytoestrogens and the relevant data available, the SCCS concluded that the use of Genistein in cosmetic products up to a maximum concentration of 0.007% is safe. However, the SCCS was not able to carry out risk assessment to concluded on the safety of the use of Daidzein in cosmetic product, as the currently available information is not sufficient to exclude the potential genotoxic effects of this ingredient.

The SCCS preliminary opinion is open for comments until 14 March 2022.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on Genistein and Daidzein. SCCS/1641/22. 2022.

further
reading

cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »
cosmetic products

European Commission Recommendation on the Definition of Nanomaterial

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. The European Commission has published a new Recommendation to clarify the definition of ‘nanomaterial’. This definition may serve different policy, legislative and research purposes when addressing materials or issues concerning products of nanotechnologies.

Read More »
cosmetic products

Expected Restriction on the Use of Methyl Salicylate

The European Commission has notified the World Trade Organization (WTO) of a draft amendment to the Regulation (EC) No. 1223/2009 on cosmetic products. Annex III to Regulation will be amended, and the use of Methyl Salicylate in cosmetic products will be restricted.

Read More »